Localised small bowel adenocarcinoma (stage I to III, resected): lines of therapy
5 standard-of-care settings across 2 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Diagnosis and staging | Endoscopy or enteroscopy with biopsy, CT of chest, abdomen and pelvis, mismatch repair testing and germline assessment. | NCCN Guidelines: Small Bowel Adenocarcinoma | 94 | |
| All comers | Surveillance | CT and CEA every six to twelve months; endoscopic surveillance of the remaining duodenum in FAP. | NCCN Guidelines: Small Bowel Adenocarcinoma | 66 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Duodenal tumours | Pancreaticoduodenectomy for proximal duodenal tumours; segmental resection for distal duodenal tumours; endoscopic resection only for adenomas. | NCCN Guidelines: Small Bowel Adenocarcinoma | - | |
| All comers | Jejunal and ileal tumours | Segmental resection with wide mesenteric lymphadenectomy; right hemicolectomy for terminal ileal tumours. | NCCN Guidelines: Small Bowel Adenocarcinoma | - | |
| All comers | After surgery | Observation for stage I and low-risk stage II; adjuvant CAPOX or FOLFOX for stage III and high-risk stage II, extrapolated from colon cancer pending BALLAD. | NCCN Guidelines: Small Bowel Adenocarcinoma | 94 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.